Cognitive behaviour therapy plus aerobic exercise training to increase activity in patients with myotonic dystrophy type 1 (DM1) compared to usual care (OPTIMISTIC) : study protocol for randomised controlled trial by van Engelen, Baziel et al.
TRIALS
van Engelen and The OPTIMISTIC Consortium Trials  (2015) 16:224 
DOI 10.1186/s13063-015-0737-7STUDY PROTOCOL Open AccessCognitive behaviour therapy plus aerobic exercise
training to increase activity in patients with
myotonic dystrophy type 1 (DM1) compared to
usual care (OPTIMISTIC): study protocol for
randomised controlled trial
Baziel van Engelen and The OPTIMISTIC ConsortiumAbstract
Background: Myotonic dystrophy type 1 (DM1) is a rare, inherited chronic progressive disease as well as an autosomal
dominant multi-systemic disorder. It is probably one of the most common adult forms of muscular dystrophy, with a
prevalence of approximately 10 per 100,000 people affected. With 733 million people in Europe, we estimate that
75,000 people in Europe are affected with DM1.
Methods/Design: OPTIMISTIC is a multi-centre, randomised trial designed to compare an intervention comprising
cognitive behavioural therapy (CBT) plus graded exercise therapy against standard care. Participants will be recruited
from myotonic dystrophy clinics and neuromuscular centres in France, Germany, the Netherlands and the United
Kingdom. A sample size of 208 individuals is needed. To allow for some potential loss to follow-up, a total of 296
male and female patients aged 18 years and older with genetically proven classical or adult DM1 and suffering
from severe fatigue (only DM1 patients with a Checklist Individual Strength (CIS) subscale fatigue severity score ≥35 are
likely to benefit from the intervention), able to walk independently and able to complete the trial interventions will be
included.
The primary outcome of the study is the score on the DM1-Activ scale, which is a measure of activity and participation
for patients with DM1. Secondary outcomes include the 6-minute walk test, objective physical activity measured with
an accelerometer, quality of life and cognitive measures. The trial will also collect data on potential effect modifiers of
the short- and long-term clinical response, including pain, muscular impairment and cognitive-behavioural variables. In
addition, OPTIMISTIC will identify genetic factors that predict outcome and potential biomarkers as surrogate outcome
measures that best explain the observed clinical variation.
Discussion: OPTIMISTIC will not only provide effectiveness data on an intervention that could fill a treatment-gap for
DM1 patients but will also improve our understanding of the relevant determinants of the prognosis of DM1.
Trial registration: Registration number: Cinicaltrials.gov NCT02118779; registered 11 April 2014.
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Myotonic dystrophy type 1 (DM1) is a rare, inherited,
progressive disease as well as an autosomal dominant
multi-systemic disorder. It is one of the most common
adult forms of muscular dystrophy, with a prevalence of
approximately 10 per 100,000 people affected [1, 2].
With 733 million people in Europe, we estimate that
75,000 are DM1 patients [3]. Typical symptoms of the
disease include progressive muscle weakness and wast-
ing from distal to proximal, ptosis; weakness of facial,
jaw and anterior neck muscles; myotonia; daytime
sleepiness; fatigue and cataracts. Other symptoms of
adult DM1 include cardiac conduction defects, as well
as endocrine, gastrointestinal and cognitive dysfunction.
DM1 is one of the most variable human diseases, has
complex, multi-systemic and progressively worsening
clinical manifestations and leads to severe physical im-
pairment, restricted social participation and premature
death [4, 5].
There is no pharmaceutical treatment for causal or
symptomatic relief of DM1 core symptoms, with the
exception of Modafinil for excessive daytime sleepiness
and mexiletine for myotonia. Thus, the aim of treat-
ment is to relieve impairments, reduce limitations and
optimise participation. Physical activity has been acknowl-
edged as an important factor for health in general. For
patients with a slowly progressive neuromuscular dis-
ease, such as DM1, there is accumulating evidence for pre-
scribing low-to-moderate-intensity strength and aerobic
exercise training, and an active lifestyle [6]. Nevertheless,
recent reviews conclude that existing studies are limited in
number and quality, and that there is a need for disease-Fig. 1 Determinants of health status in DM1. Exercise therapy is intended t
intended to stimulate an active life-style by addressing perpetuating factor
disturbances and also by teaching patients to compensate for a lack of initspecific, randomised, controlled trials investigating the
effect on quality of life [6–8].
Rationale for the study
It was demonstrated recently by OPTIMISTIC Partner 1
(see The OPTIMISTIC Consortium for list of partners)
that severe fatigue, defined as a score equal to or higher
than 35 on the subscale fatigue of the Checklist Individ-
ual Strength (CIS-fatigue), was reported by around 70 %
of patients with DM1 [9]. These severely fatigued pa-
tients had more problems with physical and social func-
tioning as well as with their mental and general health
than similar patients without severe fatigue. They also
had more problems with concentration and planning. As
such, experienced fatigue should be clearly distinguished
from muscle weakness, which is probably the most com-
mon and characteristic symptom of DM1 and also of a
lack of initiative (apathy) that is known to occur often in
DM1.
In a longitudinal study, we built a model of perpetu-
ating factors for fatigue in patients with DM1 (Fig. 1).
It appeared that lack of physical activity, sleep distur-
bances and pain all contributed to experienced fatigue.
In addition, loss of muscle strength and pain contrib-
uted to fatigue through a lower level of physical activ-
ity. Ultimately, experienced fatigue and physical activity
both contributed to the level of societal participation
[10]. A lack of initiative (motivation in the model of
Fig. 1) further increased fatigue but also had a direct
negative effect on societal participation. Thus, theoret-
ically, in order to improve societal participation one
should compensate for a reduced initiative, optimiseo improve physical activity whereas cognitive behavioural therapy is
s of fatigue such as lack of physical activity, motivation, pain and sleep
iative (motivation)
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viate fatigue one should address the fatigue maintaining
factors identified by the model, for example, experience of
pain or sleep disorders.
The main rationale for the combination of CBT and
physical exercise training is based on our DM1-specific
model [10] (Fig. 1). The DM1-specific model shows that
physical activity, experienced fatigue and lack of initia-
tive are the main determinants of DM1 health status.
OPTIMISTIC is the first model-based clinical trial in
DM1. It evaluates the effect, and the maintenance of ef-
fects, of CBT combined with exercise training on the
reduction of chronic fatigue in patients with DM1.
Importantly, the intervention will also involve care-
givers where they are willing to take part. The disabil-
ities associated with DM1 put considerable strain on
caregivers and can also lead to a negative interaction
with the patient. The intervention will aim to support
caregivers by installing realistic expectations about
what can be expected from the patient, teach care-
givers how to help patients to stay as self-reliant as
possible and also reduce caregivers strain by taking
time for themselves. If a DM1 patient has no caregiver
or significant other, or no caregiver or significant other
willing to take part in the study, the patient will not be
excluded from the study. All patients will be asked if
the study team can approach him or her to inform
them of further research. This contact does not constitute
consent.
Objectives
Primary objective
The primary objectives of this study are to evaluate the
effect of a tailored behavioural change intervention
comprising CBT and graded exercise on participation
(as measured by the DM1-Activ scale) for severely fa-
tigued patients with myotonic dystrophy type 1 compared
to standard care.
Secondary objectives
The secondary objectives of this study are as follows:
1. the creation and introduction of evidence based clinical
guidelines on exercise and cognitive behavioural
therapy combined with graded exercise in DM1,
2. the identification of individual (serum,
deoxyribonucleic acid (DNA)) or composite
biomarker profiles as surrogate outcome measures
and moderating or mediating factors of the efficacy
and safety of the clinical response, and
3. the creation of a clinical trial infrastructure for
European DM1 trials, including the collection of
natural history data from a large cohort of DM1
patients.Methods/Design
Study description
OPTIMISTIC is a two-arm, multi-centre, randomised
controlled trial designed to compare cognitive behavioural
therapy, plus graded exercise against standard patient
management regimes. It is expected that the trial and out-
come work will lead to new clinical guidelines for DM1
management. The intervention comprises cognitive be-
havioural therapy (CBT) and graded exercise therapy, both
of which aim to achieve a more active lifestyle.
The effectiveness of this intervention, together with any
adverse events associated with it, will be compared to
standard patient management. Outcome measures will be
measured at baseline; 0 to 5 week period depending if
separate screening and baseline visits are required, 5
months (± 1 month, 10 months (± 1 month, the end of
the intervention period) and at 6 months (± 1 month)
post intervention (that is, 16 months from baseline,
Fig. 2).
The baseline period constitutes either a combined
screening/baseline visit if the genetic diagnosis of DM1
is confirmed or a separate screening visit, in which to
obtain a blood sample for DM1 genetic status, followed
by a baseline visit, if confirmed. Depending upon the
medical and DM symptom history obtained from non-
confirmed participants, they may carry out all screening
and baseline activities while awaiting the genetic con-
firmation. This will allow those participants to enrol into
the screening phase of the study prior to genetic con-
firmation. It is of the opinion of the specialists that non-
confirmation will occur in very few cases.
Participants will not be blind to allocation, but the
study outcome measures listed in the Appendix will be
collected by staff who are blind to allocation.
Study population
Number of participants
Participants will be recruited from myotonic dystrophy
clinics and neuromuscular centres in the UK, the
Netherlands, Germany and France. A total of 296 (male
and female) patients will be recruited (see Inclusion cri-
teria and Exclusion criteria). The figure of 296 allows for
drop-outs; 208 are needed to complete the study with
regard to our primary outcome (the DM1-Activ scale).
This sample size for the primary outcome means that the
study is also powered for one of the secondary outcomes,
the 6-minute walk test. See Sample Size Calculation for
more details with regard to participant numbers.
Participants will be randomised to receive a 10-month
tailored behavioural change intervention (n = 148) or
standard care (n = 148). The flow of participants through
the trial is shown in Fig. 3.
For the biomarker study and DNA analysis, whole
blood will be collected in a standardised manner from
Fig. 2 OPTIMISTIC patient pathway. Visit 1 and visit 2 can be combined if appropriate and acceptable to participant. Duplicate tests and
questionnaires will not be performed
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ml whole blood samples collected per patient and sent to a
central sample storage facility, the University of Newcastle
Biobank. This facility will undertake DNA and serum
preparation and send one whole blood sample per par-
ticipant to Nijmegen University for ribonucleic acid
(RNA) preparation.
Samples will be collected at baseline, 10 months (the
end of the intervention period) and at 6-month post-
intervention (that is, 16 months from baseline). All
samples will be obtained, processed and stored as per
the Study Operations Manual, which addresses local
policies and guidelines.
Inclusion criteria
Judgements as to whether a potential participant meets
an inclusion criterion are made by the treating clinician
unless stated otherwise. Inclusion criteria are as stated
below:
1) Able to provide informed consent.
2) Genetically proven DM1, aged 18 years and older,
suffering from severe fatigue (CIS-fatigue severity
subscale score ≥35) [11]. The genetic diagnosis andlevel of fatigue will be determined as part of the
eligibility screening process.
3) Ability to walk independently (ankle-foot orthoses
and canes are accepted).
Carers inclusion criteria involve the ability to give in-
formed consent and to complete study questionnaires.
Exclusion criteria
Judgements as to whether a potential participant meets an
exclusion criterion are made by the treating clinician unless
stated otherwise. Exclusion criteria are as stated below:
1. Neurological or orthopaedic co-morbidity interfering
with the interventions or possibly influencing
outcomes.
2. Use of psychotropic drugs (except Modafinil, Ritalin
and antidepressants where the dosing regimen has
been stable for at least 12 months prior to screening).
If the doses of Modafinil or Ritalin increase during the
10 months of intervention/non-intervention then the
participant will be excluded.
3. Severe depression at screening as per clinical
judgement.
Fig. 3 OPTIMISTIC Study flowchart
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investigational medicinal product (CTIMP) or other
interventional study considered to influence
outcomes being evaluated in OPTIMISTIC
concurrently or within 30 days prior to screening for
entry into this study.
5. Unable to complete study questionnaires.
The exclusion criteria for carers are the inability to give
informed consent, complete questionnaires and attend
CBT sessions with participants.
Participant selection and enrolment
Identifying participants The study will be conducted
on an outpatient basis. The primary route of participant
recruitment will be through their neurologist at myo-
tonic dystrophy clinics and neuromuscular centres in
the UK, the Netherlands, Germany and France. At each
centre, the PI and neurological physicians will be
assisted by the study research nurses who will identifypotential participants by assessing inclusion and exclu-
sion criteria.
Additionally, participants will also be recruited from the
local or national registries of individuals with DM1. Cur-
rently, the registries for France, Germany, the Netherlands
and the UK contain 1,500, 500, 400 and 300 registered indi-
viduals, respectively. Registries contain patients who have
specifically shown interest in participating in research and
previously consented to be contacted about research in
which they can take part. Registries will contact all poten-
tially eligible participants providing a Patient Information
Sheet (PIS) and local contact details as well as contacting
medical professionals who have shown an interest in the
condition to increase awareness beyond the trial sites.
As DM1 is a genetic condition, it is likely that some
members of the same family will wish to participate in the
study. Immediate family members (mother, father, chil-
dren, and siblings) may request to attend together for
screening and subsequent study visits or separately at a
later date. There is no time limit on when a subsequent
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ment contamination, immediate family members will be
allocated to the same group, with the first family member
being randomly allocated and subsequent member(s) be-
ing assigned to the same group as the first. The web-based
Tayside Randomisation SysTem (TRuST) will assign the
initial family member as per stratification and minimisa-
tion criteria (see Randomisation), with subsequent family
member(s) being assigned by TRuST into the same group.
All participants will be asked for consent to allow the
study team to enquire if another member of their immedi-
ate family is enrolled into OPTIMISTIC. Their name will
be required to review the randomisation log to establish
their study ID. The study ID of the initial family member
will be entered into TRuST, thereby allowing same group
allocation.
It may be the case that the carer looks after more than
one member of the family wishing to take part. They will
be given the opportunity to participate for all family mem-
bers. However, the carer can opt to not participate at all or
to take part for one or all of the family members, whatever
is convenient for them.
Communication and dissemination A communication
strategy will be implemented involving patient organisa-
tions and patients from across Europe in order to inform
and engage the wider myotonic dystrophy community.
Information will be provided for patient organisations
to disseminate through newsletters, websites and at
conferences where appropriate. OPTIMISTIC also has
links to the global neuromuscular network TREAT-
NMD (www.treat-nmd.eu) and the progress of the
study will be announced through their established
newsletter (circulation over 3,000) allowing communi-
cation of the study to medical professionals and experts
in the field at an international level.
A dedicated project website (www.optimistic-dm.eu) will
provide local site information and provide contact details
for patients while providing background information
about the project to all interested parties. A dedicated pro-
ject newsletter will be circulated to all participants.
Lay-friendly results will be disseminated to participants
and through patient organisations, the TREAT-NMD web-
site and the OPTIMISTIC project website.
Consenting participants Potential participants recruited
via myotonic dystrophy clinics will receive a Patient In-
formation Sheet (PIS) from their physician, research
nurse or suitably qualified member of the study team
and will have the opportunity to discuss the study in
detail with study staff. With a patient’s permission,
caregivers and immediate family members will also be
invited to participate (see Interventions). Information
Sheets and consent forms have been reviewed andcontributed to by patient representatives and patient
organisations.
Potentially suitable participants registered with local
research networks and who have consented to being
contacted about research studies will be approached by
the study research nurse using the potential participant’s
preferred method of contact. Patients identified via local
patient registers will be sent Information Sheets: Brief
Patient Information Sheet and the full Patient and Carer
Information Sheets and will be asked to call or email if
they wish to participate in the study. The research nurse
or a member of the study team will then contact the
individual and answer any questions he or she may
have about the study. A contact telephone number and
e-mail address of a member of the local study team
will be included on the PIS to give the participant the
opportunity to discuss the study prior to their clinic
visit, if appropriate.
Those participants who have received the PIS in the
post will be asked to call/email or return the reply slip
if they wish to participate in the study. A log will be
kept by the research nurses or a member of the study
team of all participants invited to participate. For those
participants who received the PIS prior to their routine
clinic appointment and had the opportunity to ask
questions and wish to proceed to screening on that day,
informed consent will be obtained and, if appropriate
and convenient for the patient, they will then proceed
to study procedures as outlined in Fig. 2 and Appendix.
Alternatively, a convenient appointment will be made
for another date. A patient specific section of the study
website (www.optimistic-dm.eu) containing PISs and
research staff contact details will be available in the
various languages. The research nurse or a member of
the study team will contact participants who have been
sent the PIS after 10 days if they have not responded to
make sure they had received the PIS and do not wish
take part in the study.
Participants approached at a clinic, or who have received
study information from their neurologist and have in-
dicated interest by returning the reply slip, e-mailing
or calling the study team will be invited to attend a
study screening or combined screening/baseline visit if
appropriate. All participants will be given at least 24 h
to consider their response. Informed consent will be
obtained by the PI, the research nurse or a suitably
qualified and trained member of the study team as re-
corded on the Site Delegation of Responsibilities Log.
We will obtain informed consent from all participants
taking part in OPTIMISTIC.
All individuals taking informed consent will have received
training in Good Clinical Practice (GCP) and trial informa-
tion and procedures specific to OPTIMISTIC. It will be ex-
plained to patients that they are under no obligation to
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ing the trial without having to give a reason. A copy of the
signed participant consent form, along with a copy of the
PIS, will be given to the study participant. The original
signed consent form will be retained at the study site and
filed in the Investigator Site File (ISF), with a copy in the
medical notes. The participant’s general practitioner (GP)
will be informed of their study participation as per clinical
and national requirements. Consenting carers will receive a
copy of their consent form and PIS with the original being
filed in the ISF.
If new safety information linked to the interventions be-
ing evaluated results in significant changes to the study
risk-benefit assessment, the Protocol, participant PIS and/
or consent form will be reviewed updated and amended as
necessary. All participants, including those already being
treated, will be informed of the new information, given a
copy of the revised consent form and asked to re-consent
if they choose to continue in the study.
Participants and carers will be invited to complete
a series of questionnaires at each study visit. Ques-
tionnaires should be attempted but due to patient fa-
tigue portfolio a priority list will be developed and
those not completed will be documented as missing
data and is reflective of carrying out a study in a
fatigued population (Fig. 2). In addition, all study
assessments not completed will be documented as
missing data.
Ineligible and non-recruited participants The reason(s)
for ineligibility will be explained to all individuals who
are clearly not eligible, or who provide consent but then
fail screening. Any questions they have will be answered.
They will be thanked for their participation in screening
and any relevant clinical information will be added to
their hospital notes. The study team will document the
patients past medical history and specific DM1 disease
progression history. For some patients this may be an
extensive report; therefore, the researcher will obtain
the information at screening and/or at baseline visit if
required.
Outcomes
See Appendix for the trial outcome measurement schedule.
Primary outcome
The primary outcome measure will be the DM1-Activ
measured at the end of the 10-month intervention
period. DM1-Activ is a specific outcome measure of ac-
tivity and participation for patients with DM1 [12].
Secondary outcomes
Secondary outcomes are categorised into five groups:1. Activity (measurement time 50 min)
 6-minute walk test (6MWT) with BORG Scale
assessment (0 to 10 rating of perceived exertion score)
 Activities of Daily Living (ADL) assessment
 Myotonic Dystrophy Health Index (MDHI)
 Physical activity measured with an actometer (NB:
participants take this home after each visit and wear
for 2 weeks).
2. Fatigue and sleepiness (10 min)
 Fatigue and Daytime Sleepiness Scale (FDSS)
 Checklist Individual Strength (CIS) subscale fatigue
severity
3. Quality of life (20 min)
 Individualised Neuromuscular Quality of Life
Questionnaire (InQoL)
4. Mood (15 min)
 Beck Depression Inventory Fast Screen (BDI-FS)
5. Cognitive (20 min)
 Apathy evaluation scale (AES)
 Stroop colour word test
Measures used as potential effect modifiers
We will collect some data to evaluate their potential as
modifiers of the effect seen in the trial:
1. Muscular impairment rating scale (MIRS);
2. McGill pain questionnaire;
3. Cognitive behavioural variables (self-efficacy scale
for fatigue (SES-28), Jacobsen Fatigue
catastrophising scale (FCS), Focusing on symptoms
(IMmQ), Illness acceptance scale, Social support list
discrepancy (SSL-D)/Interactions (SSL-I)/Negative
Interactions (SSL-N);
4. Trail making test; and
5. Adult Social Behaviour Questionnaire (ASBQ).
Identification of biomarkers and expansion of the
dystrophia myotonica-protein kinase cytosine, thymine,
guanine (CTG) repeats
Whole blood will be collected in a standardised manner
from all 296 DM1 participants enrolled in the trial, with
3 × 10 ml whole blood samples and up to 20 ml urine
sample collected per patient. These will be used for bio-
marker identification and for genetic work linked to the dys-
trophia myotonica-protein kinase (DMPK) CTG repeats.
Identification of biomarkers
mRNA and microRNA expression changes in serum
samples will be collected for each participant in the trial
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will be paid to the expression of candidate microRNAs
relevant to the following targets in addition to any others
selected from initial next generation RNA sequencing
studies in the discovery cohorts:
1. insulin receptor,
2. muscle chloride channel,
3. SERCA1,
4. RyR1 and
5. troponin T.
The following microRNA targets will be assessed in
addition to any further selections based on other sources:
1. miR-1,
2. miR-133b,
3. miR-29 and
4. miR-206.
Expansion of CTG repeats
The blood samples collected for DNA extraction will
also be collected at the baseline and at the end of the
observation period (that is, 16 months after the start of
the intervention or control). Also, historical DNA sam-
ples will be collected, if available, to inform analysis of
disease progression. DM1 is caused by the expansion of
CTG repeats in the DMPK gene. Disease severity is cor-
related with the number of repeats. However, the CTG
repeats are highly unstable and the number of repeats
changes from one generation to the next and throughout
life. Recent data have indicated that the major modifier
of disease severity is the number of CTG repeats inher-
ited and that disease severity is further modified by the
individual specific rate of somatic expansion [13, 14].
The time series of DNA samples collected will be used
to estimate the number of repeats inherited and monitor
the rate of change of the repeat length over time in each
patient.
Cardiac magnetic resonance image sub-study
Cardiac magnetic resonance imaging (CMRI) uses a
combination of harmless radiofrequency (RF) waves and
powerful magnets to cause hydrogen nuclei within the
cardiac cell molecules to vibrate and emit RF energy.
The MRI scanner detects the energy emissions and con-
verts them to viewable images. When diseases begin,
there are changes in the heart’s tissue. Because even
minor changes in tissue affect the rates at which energy
is emitted, many medical conditions can be detected at
their very early stages. MRI is safe; there is no ionizing
radiation, and the contrast agents are non-nephrotoxic
and non-allergenic. Until recently, the use of MRI in de-
tecting heart disease was limited due to the technicalchallenges of imaging a moving object. Hardware ad-
vances and improvement in pulse sequence design now
permit high resolution imaging of the beating heart,
allowing physicians to view cardiac motion in a way not
previously possible. MRI is done to evaluate the struc-
ture and function of the heart and blood vessels. MRI
may provide information that cannot be obtained by
other tests such as chest X-ray, electrocardiography
(ECG), echocardiogram, or nuclear tests.
The study CMRIs will be performed at the Newcastle
Centre (NMRC) at baseline and repeated at the end of the
intervention period. The CMRI examinations will be per-
formed with the contract enhancement gadolinium, in 40
eligible participants, with 20 in each group. Participants
will undergo:
1. cardiac cine imaging, to evaluate cardiac
morphology;
2. systolic and diastolic function; and
3. cardiac tagging to evaluate wall motion and torsion.
These measurements will be taken with the partici-
pants lying supine within a Philips 3T MRI scanner.
After a short break, participants will lie in the scanner
prone for phosphorus magnetic resonance spectroscopy,
to measure the ratio of polymerase chain reaction (PCr)/
adenosine triphosphate (ATP), a measure of steady state
metabolite use.
MRI safety will be established prior to baseline and
end of intervention scan. This includes; assessing for
in vivo ferrous material, claustrophobia, abnormal renal
function and pregnancy. The PI will assess renal func-
tion from the participant’s medical notes at screening, if
required a blood tests for urea and electrolytes (U&Es)
will be requested. In addition, child-bearing potential fe-
male participants will consent to have a urine pregnancy
test performed.
Participants that have had a baseline CMRI and with-
draw from the study prior to the end of the intervention
period, will be invited to have an end of study CMRI if
the period from their initial CMRI is greater than 3
months. No further statistical review is required for the
CMRI sub-study as only frequencies and associations
will be assessed.
Magnetic resonance muscle (MRmuscle) sub-study
Magnetic resonance (MR) biomarkers that have been
found to be extremely useful in the evaluation and un-
derstanding of other muscular diseases (that is, facios-
capulohumeral muscular dystrophy (FSHD)) are the
fractional muscle and fat levels in muscles and the
presence of inflammation [15]. It was observed that the
fat infiltration measured in this way already occurs be-
fore clinical symptoms or decline in muscle force is
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uted both intra- and intermuscular and from the time
dependence of this pattern a characteristic progression
of the disease was established that could be related to
the origin of the disease.
This sub-study will perform MR in the upper and
lower legs of DM1 patients to establish the value of fat
infiltration as a biomarker of the disease. In addition, the
presence of oedema will be estimated using the so called,
turbo inversion recovery magnitude (TIRM) sequence as
a biomarker of inflammation. These biomarkers will be
followed quantitatively during the treatment interven-
tion. MRmuscle is a non-contrast MR.
The overall aim of this MRmuscle sub-study is to obtain
MR biomarkers that can be used as clinical endpoints for
therapeutic interventions in patients with myotonic
dystrophy. This sub-study will only be performed in
two of the participating sites; Radboud University Medical
Centre, Nijmegen and Centre hospitalier universitaire
Henri-Mondor, Paris. Based on previous findings in FSHD,
the desired number of participants will be at least 30 (15
from the intervention group and 15 from the comparison
group). Taking into account potential loss to follow-up,
the study will aim to recruit up to 50 patients to meet the
target of 30 completed sets of MR data. The number of
participants per centre may not be equally divided (for
example, Nijmegen 20 and Paris 30 participants.) This
multi-centre design increases the credibility of the
MRdata. Each participating centre will employ its own
quality assurance program/procedure. This procedure
is inherit within each MR department and usually allows
the study MR protocol to be carried out initially on a
normal volunteer to set baseline parameters.
Participants that are eligible for the OPTIMISTIC
main study and have no contraindications for MRI can
be included in the MRmuscle sub-study. The MRmuscle
sub-study will stop recruiting once 50 participants have
been recruited, or the OPTIMISTIC main study stops
recruiting, whichever comes first.
MR contraindications will be as per local guidelines
but will include having metal parts in the body, having a
pacemaker, claustrophobia, being unable or unwilling to
tolerate the loud noises made by the MR machine and a
body mass index (BMI) that is contraindicated for fitting
comfortably into the MR scanner.
Patients will receive information for MRI together with
the main OPTIMISTIC participant information. The MR
informed consent form will be signed at the same time
as the main OPTIMISTIC informed consent form. It
will be possible for a participant to consent to the main
OPTIMISTIC study but not the MRmuscle sub-study.
MR measurements will be performed on a 3T MR sys-
tem (TIM Trio, Siemens, Erlangen, Germany). Patients
will undergo an MR for the upper and lower legs. Prior toMR imagining a fish oil capsule will be positioned at one
third of the distance between the spina iliaca anterior su-
perior and the patella and will serve as a landmark for
exact matching of the imaging slices between the baseline
and follow-up measurement. The total time of the meas-
urement is approximately 30 min. Measurements will be
performed during the baseline period, before the first CBT
session for those randomised into the intervention group
and repeated at the end of the intervention period for all
participants. For participants that have had a baseline MR
and withdraw from the study prior to the end of the inter-
vention period, these participants will be invited to have
an end of study MR if the period from their initial MR is
greater than 3 months.
Baseline biomarker values will be collected for the
following:
1. cross sectional area of muscle,
2. muscle/fat quantification, and
3. signal intensity per region of interest (ROI) oedema.
This data will be used to:
1. investigate whether there is a relation with the state
of the disease and
2. investigate whether these values change due to the
intervention, that is, comparison with patients in the
control group.
Differences between affected and non-affected muscles
will be correlated with each other and with the values of
various parameters determined in OPTIMISTIC (for ex-
ample, muscle strength). Specific biomarkers established
for DM1 will then be used to evaluate the effect of the
CBT intervention.
The acquired MR images will be anonymised and will
only contain participant’s study ID.
In Nijmegen, the anonymised data will be stored on a
hospital server. In Paris, the anonymised data will copied
onto an encrypted CD or DVD and sent by courier to
Nijmegen where the data will be uploaded onto the ser-
ver for analysis by the MR research team.
Randomisation
Randomisation will be via a centrally controlled web-based,
GCP-compliant randomisation system, run by Tayside
Clinical Trials Unit (TCTU) called TRuST (Tayside
Randomisation SysTem).
Randomisation will occur as indicated below:
1. It will be stratified by site.
2. It will be minimised for baseline DM1 severity
measured by the Muscular Impairment Rate Scale
(MIRS) 5-point scale.
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of a caregiver.
For immediate family member participation TRuST will
assign the initial family member as per stratification and
minimisation criteria (see Randomisation), with subse-
quent family member(s) being assigned by TRuST into
the same group. All participants will be asked for consent
to allow the study team to enquire if another member of
their immediate family is enrolled into OPTIMISTIC.
Their name will be required to review the randomisation
log to establish their study ID. The study ID of the initial
family member will be entered into TRuST thereby allow-
ing same group allocation.
Intervention allocation
Participants will be randomly allocated in a 1:1 ratio* to
receive the intervention, or standard patient care. *Except
for immediate family member participation (see section
Randomisation).
Withdrawal procedures
Withdrawal from randomised therapy
Any clinician involved in the usual care of patients may
withdraw patients from randomised intervention therapy
using his/her clinical judgement. This might occur due
to the occurrence of an adverse event and the onset of
symptoms that limit tolerability. Participants withdrawn
from randomised intervention therapy will remain in the
study and will be included in the primary intention-to-
treat analysis unless they request that their data are re-
moved. If withdrawal is due to an adverse event it will
be logged as such on the Adverse Event Log. All reasons
for withdrawal will be noted in the participant’s Case Re-
port Form and medical case notes. The participant and
carer will be invited to attend the withdrawal visit. The
measurements and activities scheduled at Visit 5 will be
performed in the priority set out in the schedule
table Appendix incorporating the participants and carers
preferences. If a participant is randomised into the study
with an immediate family member and either withdraw
the other will be able to continue in the study.
Withdrawal of consent to follow-up
If at any time the patient formally withdraws his/her
consent for future participation and disclosure of future
information, no further evaluations will be performed
and no additional data should be collected. Data col-
lected before such withdrawal will be retained and used
in the study analysis (with consent).
Temporary suspension of randomised therapy
Temporary discontinuation (no time limit) of rando-
mised therapy may be permitted for justifiable reasons.These periods must be logged accurately. This is import-
ant as a secondary analysis will include an ‘on therapy’
versus ‘off therapy’ component using data collected as
part of the intervention.
Participant retention
Due to the complex nature of the condition every effort
will be made to ensure participant retention and adher-
ence to the protocol. Patients will be contacted by phone
the day prior to each scheduled visit. A study website will
also be available for participants to catch-up on study pro-
gress (www.optimistic-dm.eu).
Interventions
Behavioural change intervention
In the OPTIMISTIC study patients in the treatment arm
will receive cognitive behavioural therapy plus graded
exercise therapy. The behavioural change intervention is
aimed at increasing the activity level and participation of
patients by addressing three core problems thought to
maintain disabilities:
1. severe fatigue,
2. a reduced initiative and
3. suboptimal interaction with significant others.
It is assumed that CBT will reduce these problems and
thus enable DM1 patients to become more active. The
intervention is based on a model of fatigue and disability
in DM1 and evidence-based cognitive behavioural inter-
ventions for patients with other chronic medical condi-
tions. Intervention group participants will continue to
receive standard clinical care as judged necessary by
their treating clinicians.
It should be noted that some parts of the intervention
are targeted at the caregiver or significant other. If a
DM1 patient has no caregiver or significant other, or no
caregiver or significant other willing to take part in the
study, the patient will NOT be excluded from the study.
For brevity, we will use ‘caregiver’ in the following text
but this should be taken as meaning ‘caregiver or signifi-
cant other’.
CBT consists of six different modules. All patients will
start with individual goal setting and psycho-education
about the role of cognitive-behavioural variables in the
disabilities patients’ experience. The patient formulates
his or her treatment goals in concrete terms and later on
in the therapy the goals are realised step by step by the
patient. The treatment is tailored to the patient’s prob-
lems: which of the six modules a patient will receive is
dependent on the scores on measures that have been
collected at baseline assessment. The extra measures for
the baseline assessment will take about 40 min. They
will be used to assess elements relevant for CBT that
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enable us to do mediation analysis to determine to what
extent the changes in cognitions and behaviour mediate
the expected positive effects of the intervention on the
outcome measures. If a patient is not able to fill in the
questionnaires, it is unlikely that the patient can profit
from the intervention and will not be randomised. Based
on our previous experience with modular interventions
we expect that most patients will receive less than four
modules. The six modules are described below:
1. Learning to compensate for a reduced initiative.
After psycho-education patients learn how to
compensate for a reduced initiative by using cues
to initiate activity. Examples of these cues are
using a diary, mobile phone with an alarm or the
scheduling of activities. Caregivers will also be
taught how to cue behaviour and how to stimulate
the patients to use cues. The goal of this module is
to help the patient to start more activities. This
module is indicated if a patient scores higher than
38 on Apathy Evaluation Scale (AES). The AES is
filled in by the caregiver and/or clinician (or
trained assessor) during the intake session. The
caregiver is asked to participate in the intervention
and to fill in some of the questionnaires. However,
if the caregiver refuses or cannot participate, the
patient can still take part in the trial.
2. Suboptimal interaction with caregivers. The
disabilities associated with DM1 put considerable
strain on caregivers and can also lead to a negative
interaction with the patient. The patients can also
feel misunderstood by others, which further
hampers their interactions with others. The goal of
this module is to optimise the interaction with
caregivers by installing realistic expectations about
what can be expected from the patient, teach
caregivers how to help patients to stay as self-reliant
as possible and also reduce caregivers strain by taking
time for themselves. The expectations of the patient
about the support of others will be discussed and the
patient is stimulated to adequately ask for support
where possible. This module is indicated if 1) a proxy
scores 7 or higher on the Caregiver Strain Index (CSI),
2) the partner and/or patient score 60 or lower on the
Marital Satisfaction VAS, or 3) the patient scores 14 or
higher on the subscale discrepancy (SSI-D) of the
social support inventory (short form).
The following 4 modules are specifically aimed at
fatigue maintaining behaviours and beliefs:
3. Regulation of the sleep-wake pattern (completed
for all participants). The importance of a regularsleep-wake cycle and good sleep hygiene are
discussed, and instructions will be given how to
improve both. At baseline patients will register
bedtime, get-up times and sleeping during the day
for 2 weeks. This will be noted by the patients using
a diary. This is plotted in a bar chart to visualise
irregularities in the patient’s sleep-wake cycle. This
module is indicated if the patient has an irregular
sleep-wake cycle and/or scores 60 or higher on the
subscale sleep of the Sickness Impact Profile (SIP).
4. Reformulation of dysfunctional cognitions with
respect to fatigue and/or DM1. At baseline the
sense of control over fatigue symptoms, fatigue
catastrophising and the tendency to focus on fatigue
are assessed. This module is indicated if a patient
has a problematic score on one or both of the
following instruments: Self-efficacy Scale for
fatigue (score 19 or lower), and the Jacobsen
Fatigue Catastrophising Scale (score 16 or higher)
or a score of 4 or higher on the Illness Management
Questionnaire. Helping beliefs with respect to fatigue
are formulated and patients practice with them. Patients
will also practice with redirecting the focus of attention
away from the fatigue toward activity and other
sensations. If a patient has dysfunctional beliefs
about the illness, for example, has difficulty accepting
the fact of being ill, helping belief will be formulated.
This intervention will be done if a patient scores in
the problematic range on the Pictorial Representation
of Self and Illness Measure (PRISM), the Beck
Depression Inventory Fast Score - (BDI-FS 6
Protocol ≥ 4) or subscale Illness acceptance (≤12).
5. Activity regulation and graded activity. Physical
activity will be assessed using an ankle or wrist worn
actometer (GeneActiv/Kinesense or equivalent CE
marked device). The device is light weight,
waterproof and has been adapted for long wear. It is
often worn by sports men and women to measure
activity progress. Full detailed instructions will be
given to the patients at screening/baseline visit. The
device will be attached using a non-metal bracelet
and patients will be instructed that it should be worn
for 14 days continuously but that it can be easily
removed by the participant if required by cutting
the bracelet with a pair of scissors. The actometer
will be worn for 14 days after the screening/baseline
assessment to define what activity measures are in
place. Relatively active patients first have to distribute
their activities more evenly followed by a gradual
increase of physical activity. At baseline patients
will choose an activity programme with the
counsellor, either a low intensity, graded physical
activity program and an exercise program aimed at
an increased physical fitness:
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that they walk, OR
b. an exercise program aimed at increasing their
physical fitness. The exercise programme will be
defined through the counselling but will target
incorporating moderate intensity exercises such
as walking, cycling, jogging or dancing for at least
half an hour, three times a week. After
participants have increased their physical activity
level or fitness they start to increase other
activities in order to reach their goals.
The Actometer
The device will be worn for 14 days continuously
after screening or baseline and at months 5, 10
and 16. Additional use may also be suggested by
the counselling to assist behaviour change. The
device will be fitted at a visit, worn for 14 days,
removed and then returned to the trial site by
post in a stamped addressed padded envelope.
The actometer itself is a tri-axial STMicroelectronics
accelerometer and the acceleration will be sampled
at 50 Hz. Raw data is transferred through USB to
PC and analyses according to patient ID on
MOVEeCloud.
Non-Wear time
Results for a given 14-day period will be deemed
invalid if non-wear time exceeds 50 % duration.
Where non-wear time is less than 50 % the results
will still be used and the non-wear time will be
accounted for by imputation of the non-wear time
using available wear time data at similar times on
other days for the given participant.
Control
Those not randomised to the intervention will
also be invited to wear the actometer for 14 days
immediately after visits at screening/baseline,
months 5, 10 and 16. The device will be returned
by post in the same way as for intervention group
participants.
6. Coping with pain with a focus on dysfunctional
cognitions with respect to pain. Dysfunctional pain
cognitions are disputed. More helpful pain-related
cognitions will be installed. This module is indicated
if a patient has a problematic score on the SF36 pain
subscale (score lower than 60) or 44 on the VAS
pain.
The intervention will be delivered by therapists who
have received extensive training before the trial starts
and will use a standardised treatment manual developed
by the OPTIMISTIC team. Prior to participating in the
graded activity module, the treating clinician will make a
judgment as to the degree of physical activity the partici-
pant is safely capable of doing, which will be communicatedto the therapists. The therapists will remain in contact
with the treating clinician throughout the trial to discuss
any changes. The therapists and/or the research nurse can
request that the treating physician/Investigator to review
the patient at any time if any of the research team, the
patient or the carer have any concerns. If required, the
patients’ GP will be informed.
Participants will receive a workbook containing rele-
vant information and assignments. If deemed appropri-
ate a patient may be given a gym membership to assist
with their set goals. If participants give their permission,
CBT sessions will be audio recorded and transcribed.
Transcriptions will be anonymised. Audio recordings
will be stored securely at local sites and destroyed as de-
scribed under Study record retention.
Between sessions participants will do ‘home-work’ as-
signments that are discussed in the subsequent session.
If caregivers are involved in the intervention, they will
be asked to support the patient in carrying out these as-
signments. Treatment integrity will be determined by
two experienced cognitive behavioural therapists, who
will independently rate a random selection of audio-
taped sessions. During the intervention period phone
calls to participants will be made at least once a week
between sessions to remind them to complete any
homework and to ensure attendance at sessions. Where
it is felt necessary and resources allow participants will
be visited in their homes to increase adherence and pro-
vide support where needed.
The intervention runs for 10 months but is front-
loaded, meaning the first 4 months can be considered
the ‘active’ phase with the remaining 6 months in the
‘booster’ phase. In this period of 10 months a patient
will receive 10 to 14 sessions; at least 5 of them are face
to face sessions. For the other sessions the therapist can
decide, dependent on the traveling distance and the mo-
bility of the patient, to use telephone contact or video
conferencing as an alternative.
In addition, all therapists will receive one support call
every two weeks by telephone from an experienced cog-
nitive behavioural therapist in the OPTIMISTIC team,
with extra support available by email.
Comparison
Standard care is the usual care at the participating site.
This will vary by site and according to individual pa-
tient symptoms but the minimum is generally an
annual visit plus ECG/EKG. Other care may include
appropriate history taking, physical examination, ECG/
EKG (or more in depth cardiac investigations), pul-
monary and gastrointestinal investigations, and rehabilita-
tion measures.
All control group participants will visit their trial site at
baseline and months 5, 10 and 16 months post intervention
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detailed in Appendix.
Study and safety assessments
A number of factors affecting the trial population suggest
that we would expect to observe a larger than normal inci-
dence of episodes of adverse events (AEs) such as fatigue
and ill health due to co-morbidities of the study popula-
tion. All known disease progression and co-morbidities
will be noted but not reported.
Due to the large amount of co-morbid diseases that
we expect to be present in the population, we will
record, but not report, Serious Adverse Events (SAE)
in the following categories:
1. Any new cardiovascular event,
2. Any new treatment of myotonic dystrophy type 1,
3. Any hospitalisation due to falls or fractures,
4. Any hospitalisation due to exacerbation of an
existing medical condition, and
5. Any elective or planned investigation or treatment.
All unexpected SAEs (that is, an SAE that is not listed
above) will be recorded and reported to the sponsor. An
example of an unexpected SAE would be premature
death of a participant that was not due to an existing
condition.
Safety assessments will be recorded at every visit.
Data collection and management
Data collection
It is the responsibility of the local PI to ensure the accuracy
of all data entered and recorded in the CRFs and the
database for his or her site. The Delegation of Respon-
sibilities Log will identify all trial personnel responsible
for data collection, data entry and handling and managing
the database.
The data will be collected by the PI or delegate onto a
paper CRF for subsequent transcription to the eCRF.
Data entry onto the web based eCRF may be done lo-
cally or paper CRFs may be sent to an external unit for
data entry depending on local preference. If CRFs are
sent away for data entry a copy of what is sent must be
retained by the originating team. This includes patient-
completed questionnaires. The two copies must always
record the same information. This means that if values
are updated as a result of the querying process the
changes must be annotated on both copies, initialled
and dated. Both physical and electronic storage of data
will protect the security of these data and the confidentiality
of participants.
The study questionnaires will be completed according
to the schedule shown in Appendix by the participant
with the assistance of the research nurse and caregivers.Laboratory derived blood tests will be held on local clin-
ical databases in an identifiable format and for a time
frame in line with local regulations and policies for clinical
care systems. All research blood samples will be processed
and stored at each site (as per Sample Analysis and Chain
of Custody Plans in the Study Operations Manual) and
transported to the relevant laboratory for analysis at time-
frames outlined in the Study Operations Manual for batch
analysis.
The medical notes can act as source data for past
medical history, subsequent medical conditions, hospital
admissions, diagnostic reports and blood and urine results.
Data management system
A data management system will be provided by TCTU
using OpenClinica (https://www.openclinica.com/), its
standard Good Clinical Practice (GCP)-compliant data
management system. The study system will be based on
the protocol and CRF for the study and individual
requirements of the investigators. Development and
validation of the study database, quality control and ex-
traction of data will be done according to TCTU
procedures.
Statistics and data analysis
Sample size calculation
The primary outcome is the DM1-Activ scale, which is a
Rasch-built measure of activity and participation for pa-
tients with DM1 and is currently the best such measure
for these patients. Based on a minimum clinically import-
ant mean difference of 1.4 on the 40-item DM1-Activ
scale, standard deviation of 3.5 and effect size = 0.4, 80 %
power and 5 % significance level, we need a sample size of
100 in each arm, or 200 in total.
DM1 is a genetic condition so it is likely that some
members of the same family will take part in the study.
To avoid the risk of contamination, immediate family
members (mother, father, children, and siblings) will be
allocated to the same group, with the first family mem-
ber being randomly allocated and subsequent members
being assigned to the same group as the first. This
means that there will be some clusters of more than one
individual and the sample size needs to be inflated to ac-
count for this. Newcastle estimates that this may affect
50 % of their participants, the other sites estimate that
fewer than 10 % of participants will be part of a family
group. All sites estimate that almost all family groups
will comprise two individuals. Using estimates of distri-
butions of recruitment across sites (Newcastle = 23 %;
Nijmegen = 30 %; Paris = 33 %; and Munich = 13 %)
and the above family group proportions gives an average
cluster size of 1.17. Using a conservative intra-cluster
correlation coefficient of 0.20, gives an inflation factor of
1.035, meaning the recruitment target needs to be
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drop-out this gives a final sample size of 208, or 104
participants per arm.
These are conservative estimates (especially the
minimum clinically important difference). The clinical
OPTIMISTIC sites between them see well over 1,000
DM1 patients per year, which gives OPTIMISTIC a
good pool of potentially eligible participants. Around
70 % of DM1 patients are expected to be eligible for
OPTIMISTIC.
We will be using one of our secondary outcomes, the
6-minute walk test (6MWT) as an additional validation
of the DM1-Activ scale, meaning that we have also
powered this secondary outcome. The DM1-Activ sam-
ple size of 208 gives over 90 % power for the 6MWT
based on a mean difference of 40 m, standard deviation
of 80 m and a baseline of 450 m.
Proposed analysis
The primary analyses will be conducted according to the
principles of intention to treat (ITT) as outlined on the
ICH E9 ‘Statistical Principles for Clinical Trials’.
Continuous variables will be summarised by the number
of observations, number of missing values, mean, standard
deviation (SD), median, inter-quartile range (IQR) and
range. Summaries will be provided at baseline, at each
subsequent time point and for the change from baseline
by intervention group. Categorical variables will be
summarised by the number of observations, number
of missing values and number and percentage in each
category. Summaries will be provided at baseline and
at each subsequent time point.
The primary outcome and most other outcomes are
continuous and so linear models will be utilised. The
primary outcome of change in DM1-Activ will be ana-
lysed using mixed effects (repeated measures) regression
models. Models will include fixed effects for intervention
group, time point, and their interaction, plus random
effects for each subject to account for repeated mea-
sures, and will assume a general covariance structure.
A binary variable will be added to the regression model
to represent the difference between the intervention
and standard care. The minimisation variables of sever-
ity of DM1 (measured using the MIRS 5-point scale)
and caregiver involvement at baseline will also be added to
the regression model as fixed effects, as well as stratification
by site.
Intervention effect differences will be reported with
95 % confidence intervals (CIs) and P-values. Results will
also be explored and reported with additional a priori ad-
justment for potential effect modifiers (see list inMeasures
used as potential effect modifiers). Subgroup analyses will
be carried out by first testing for a subgroup factor by
intervention interaction [16]. If this is significant at the5 % level, results will be estimated separately by the dif-
ferent subgroups. These analyses will also be repeated
for all the secondary outcomes. Appropriate transforma-
tions of outcomes will be performed where necessary to
satisfy modelling assumptions.
A statistical analysis plan (SAP) will be written prior
to datalock and approved by the statistician and CI.
Analyses will be carried out using SAS.Missing data
The extent of missing data will be explored in the out-
comes especially the primary outcome. Patterns of missing
data will be explored and predictors of missingness exam-
ined, especially if these vary by intervention. If necessary,
multiple imputations will be utilised to impute missing
data assuming the missingness mechanism is missing at
random (MAR). However, mixed models have the useful
property of using all available data without resorting to
imputation where data is MAR. The assumption of MAR
cannot be pre-specified or tested as it depends on whether
and how data has become missing. Measures should be
taken where possible to minimise the extent of missing
data in the recording of outcomes so that missing data is
less likely.Transfer of data
Case Report Forms (CRF) will be developed together
with the trial management team, statistician and data
manager to ensure that the data management system
(see Data management system) supports the research
aims of the study. The data management system will be
fully validated, including the provision of test data and
supporting documentation. Data entry will be coordi-
nated by TCTU although sites will generally be doing
their own data entry. It is the PI responsibility to ensure
the accuracy of all data entered and recorded in the
CRF/eCRFs. Data will be stored on servers controlled by
TCTU and housed at the University of Dundee. Backup-up
and disaster recovery will be provided by TCTU according
to its standard operating procedures.
The study questionnaires will be completed at screen-
ing/baseline, 5-month, 10-month (that is, the end of the
intervention) and 6-month post-intervention onto a paper
CRF with subsequent transcription (where appropriate) to
OpenClinica.
All research related blood sample analysis and data
established from the NHS/health care tests will be stored
in an unidentifiable format in the password protected
disaster recovery formatted database.
All research blood samples (link-anonymised) will be
processed as per Sample Analysis and Chain of Custody
Plans in the Study Operations Manual and transported
to the relevant laboratories for analysis.
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will be sought. Finally, the Delegation of Responsibilities
Log will identify all trial personnel responsible for data
collection, entry, handling and managing the database.
Trial management and oversight arrangements
OPTIMISTIC will have the following two oversight
committees:
1. The Trial Management Committee will be
responsible for day-to-day operational issues.
2. The External Advisory Board will be responsible for
strategic decision making and issues linked to
monitoring ethical and patient safety issues, together
with monitoring recruitment and data quality issues.
Trial management committee
The OPTIMISTIC trial will be managed by TCTU. The
Trial Management Committee (TMC) will comprise the
leader of the trial component of OPTIMISTIC, senior
statistician, TCTU Assistant Director, a representative of
TCTU’s data management staff and the TCTU senior
trial manager and study trial manager. Other members
of the OPTIMISTIC group may be added as required by
the consortium or the Trials Unit. The TMC will meet
at least monthly by face-to-face and more often if
needed, especially in the early phases of the trial.
Trial/study management
Each clinical site will have a research nurse or research
associate allocated to the study who will oversee the
study and will be accountable to the local PI. The re-
search nurse or research associate will be responsible for
checking the CRFs for completeness, plausibility and
consistency. Any queries will be resolved by discussion
with the CI, or delegated member of the study team. At
every site a lead CB therapist will be responsible for the
referral of patients to an appropriate CB therapist if
they are randomised to the intervention arm. The same
CB therapist will have regular meetings with the other
therapists at the site and will oversee the flow of patients
in the intervention arm. The CB therapist will be respon-
sible for data collection at the clinical site with respect to
the intervention.
A study-specific Delegation Log will be prepared for
each site, detailing the responsibilities of each member
of staff working on the study.
External advisory board
The External Advisory Board comprises independent, inter-
national experts covering the key areas of competence re-
quired to provide oversight of OPTIMISTIC scientific
activity. The list of participants is at http://optimistic-dm.eu/
external-advisory-board/. The Board ensures a high standardof research and governance and monitors the progress of
the project. The OPTIMISTIC consortium will consult the
Board at least annually (more often if the Board requires) to
get members’ opinions with regard to study progress, espe-
cially on issues linked to the trial.
The Board will comment on ethical and safety issues as
well as general conduct issues. In addition the project will
have access to the TREAT-NMD project ethics council
(PEC) if any additional advice should need to be sought.
Inspection of records
The CI, PIs and all institutions involved in the trial will
permit trial-related monitoring, audits, and ethical review.
The CI agrees to allow each country specific sponsor or,
representatives of the sponsor, direct access to all trial
records and source documentation.
Good clinical practice
Ethical conduct of the study
The study will be conducted in accordance with the princi-
ples of Good Clinical Practice (GCP). In addition to spon-
sorship approvals, a favourable ethical opinion will be
obtained from the appropriate country specific ethics com-
mittee(s) and where appropriate local management ap-
proval(s) will also be obtained prior to the start of the trial.
Confidentiality
All laboratory specimens, evaluation forms, reports, and
other records will be identified in a manner designed to
maintain participant confidentiality. All records will be
kept in a secure storage area with limited access by ap-
propriate trial staff only. Clinical information will not be
released without the written permission of the partici-
pant, except as necessary for monitoring and auditing by
the sponsors or their designee. The CI and staff involved
with the trial will not disclose or use for any purpose
other than performance of the trial, any data, record, or
other unpublished, confidential information disclosed to
those individuals for the purpose of the trial. Prior writ-
ten agreement from the sponsors or their designee will
be obtained for the disclosure of any said confidential in-
formation to other parties.
Data protection
The CI and staff involved with the trial will comply with
the requirements of the relevant data protection legisla-
tion for their jurisdiction with regard to the collection,
storage, processing and disclosure of personal information.
The CI and trial staff will also adhere, if appropriate, to
other local regulations and policies with regard to confi-
dentiality of data. Access to collated participant data will
be restricted to the CI and appropriate trial staff.
Computers and IT systems used in connection with the
trial will have access-control measures such as centrally
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will not contain any personal data that could allow identi-
fication of individual participants.
Insurance and indemnity
Insurance Each country-specific sponsor will obtain and
hold a policy of public liability insurance for legal liabil-
ities arising from the study at each of its identified sites.
The site ISF and TMF will hold notification of sponsor
and a copy of certificate of insurance as per local spon-
sor policy.
Indemnity The country specific sponsor will provide
study participants with indemnity in relation to partici-
pation in the study but has insurance for legal liability as
described above.
Study conduct responsibilities
Protocol amendments, deviations and breaches The CI
will seek approval for any amendments to the protocol
or other study documents from the sponsor and relevant
ethics and local management committees. Amendments
to the protocol or other study documents will not be im-
plemented prior to these approvals. In the event that a
PI needs to deviate from the protocol, the nature of and
reasons for the deviation will be recorded in the CRF,
documented and submitted to the sponsor. If this neces-
sitates a subsequent protocol amendment, this will be
submitted to the sponsor for approval and then to the
appropriate ethics and local management committees
for review and approval.
In the event that a serious breach of GCP is sus-
pected, this will be reported to the site-specific sponsor
immediately.
Study record retention
The University of Dundee will archive OpenClinica elec-
tronic data and any other trial materials for five years
after trial closure. Participating sites will store their trial
materials locally according to local archiving regulations
but for not less than five years.
End of trial
The end of trial is defined as database lock. The
sponsor, CI and/or the external advisory board have
the right at any time to terminate the study for clin-
ical or administrative reasons. The end of the trial
will be reported to the sponsor and ethics committee(s)
within 90 days, or 15 days if the trial is terminated
prematurely. The CI will ensure that any appropriate
follow up is arranged for all participants. A summary
report of the trial will be provided to the sponsor and eth-
ics committee(s) (in English) within 1 year of the end of
the trial.Reporting, publications and notification of results
Authorship policy Ownership of the data arising from
this study resides with the trial team and their respective
employers. Authorship of publications coming from this
work will be in accordance with OPTIMISTIC’s publica-
tion policy.
Peer review The OPTIMISTIC proposal, including this
trial, was reviewed by external reviewers appointed by
the European Commission as part of the 7th Framework
funding review process.
Ethical approval
Version 3.2 of the protocol has received ethical approval
from the National Research Ethics Service Committee
North East - Sunderland (UK), Comite de Protection des
Personnes ile de France V (France); Ethikkommission
bei der LMU München (Germany); Concernstaf Kwaliteit
en Veiligheid Commissie Mensgebonden Onderzoek Regio
Arnhem- Nijmegen (Netherlands).
Discussion
DM1 is one of the most variable human diseases, and
has complex, multi-systemic and progressively worsen-
ing clinical manifestations. It leads to severe physical im-
pairment, restricted social participation and premature
death. The complexity of DM1 poses a challenge for pa-
tient management and treatment options are currently
extremely limited. There is a strong need to improve
clinical practice in the management of these patients
suffering from a rather neglected disease.
OPTIMISTIC is the first model-based clinical trial in
DM1 and it will provide a unique set of data. The project
will investigate the serious gaps in our knowledge of the
natural history of DM1, patient-relevant outcome mea-
sures, and evaluate the effectiveness of CBT and physical
exercise on quality of life in a trial designed to be highly
applicable to other contexts and jurisdictions. Further-
more, OPTIMISTIC will advance our knowledge of indi-
vidual and composite biomarkers of the disease. Finally,
the project will fully explore scientific questions about
moderating and/or mediating factors of the short- and
long-term clinical response, together with the short- and
long-term safety of CBTand physical activity. This body of
work will not only improve our understanding of the rele-
vant determinants of the prognosis of DM1 but will also
produce effectiveness data on an intervention that could
fill a treatment-gap for DM1 patients.
The OPTIMISTIC study started on 1/11/2012 and
will end 31/10/2016. Recruitment started on 6th April
2014.
Trial status
Ongoing and recruiting at time of submission.
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Measurement point
Priority outcome measure Time to
complete
Visit 1
Screening
Visit 2
Baseline a
Visit 3
(5 months)
Visit 4
(10 months)
Visit 5
(16 months)
1 Demographics X
General medical history X X
1 Concomitant medications & therapies X X X X X
Adverse events X X X X
1 Confirm genetically proven classical or adult DM1/specific
DM1 history
X X
Primary outcome measure
1 DM1-Activ 5 min X X X X
Secondary outcome measures
Activity
5 MDHI 20 min X X X X
2 6-minute walk test/BORG Scale 10 min X Xa X X X
13 Actometer data For 14-days
after visit
X Xa X X X
Fatigue and sleepiness
3 Checklist individual strength (CIS) fatigue 5 min X Xa X X X
11 Fatigue and daytime sleepiness scale (FDSS) 5 min X X X X
Quality of Life
6 Individualised neuromuscular quality of life (InQoL) 20 min X X X X
Mood
4 Beck depression inventory-fast screen (BDI-FS): 10 min X Xa X X X
Cognitive Measures
8 Apathy evaluation scale 10 min X X X X
12 Stroop 5 min X X X X
Potential Effect Modifiers
9 MIRS 2 min X Xa X X X
14 McGill pain questionnaire 10 min X X X X
15 Trail making 10 min X X X X
21 Adult social behaviour questionnaire (ASBQ) 10 min X X X X
Marital satisfaction (VAS) X X X X
16 CBT: self-efficacy scale for fatigue (SES-28); 4 min X X X
17 CBT: fatigue catastrophising scale (FCS) 4 min X X X
18 CBT: focusing on symptoms (IMmQ) 4 min X X X
19 CBT: Illness acceptance scale 4 min X X X
20 CBT: social support (SSL-D)/Social Support list interactions
(SSL-I)/Social support list negative interactions (SSL-N)
4 min X X X
Sickness impact profile (subscale sleep) X
Biomarkers
7 Whole blood 10 ml sample x3 (10 ml for DNA; 10 ml for
RNA and 10 ml serum).
5 min X X X
22 Urine sample (10 ml or more) x1 5 min X X X
Table 1 Trial outcome measurement schedule (Continued)
Carers measures
Caregivers strain index (CSI) X X X X
ASBQ (Other) 10min X X X X
Marital satisfaction (VAS) (can be a partner). X X X X
Will not be performed if carer is a non-partner.
Apathy evaluation scale (AES) X X X X
aVisit 1 and Visit 2 may be combined if appropriate. No duplication of tests/questionnaires performed
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ADL: activities of daily living; AE: adverse event; AES: apathy evaluation scale;
ASBQ: adult social behaviour questionnaire; ATP: adenosine triphosphate;
BDI-FS: Beck depression inventory fast screen; BMI: body mass index;
CBT: cognitive behavioural therapy; CI: chief investigator; CIS-fatigue: checklist
individual strength fatigue subscale; CMRI: cardiac magnetic resonance
image; CRF: case report form; CTG: cytosine, thymine, guanine; CTIMP: clinical
trial of an investigational medicinal product; DM1: myotonic dystrophy type
1; DMPK: dystrophia myotonica-protein kinase; DNA: deoxyribonucleic acid;
ECG/EKG: electrocardiography; FCS: fatigue catastrophising scale;
FDSS: fatigue and daytime sleepiness scale; FSHD: facioscapulohumeral
muscular dystrophy; GCP: good clinical practice; ICH: International
Conference on Harmonisation; IMmQ: illness management questionnaire;
InQoL: individualised neuromuscular quality of life questionnaire; IQR:
inter-quartile range; ISF: investigator site file; MAR: missing at random;
MDHI: myotonic dystrophy health index; MIRS: muscular impairment rating
scale; MR: magnetic resonance; MRI: magnetic resonance imaging;
mRNA: messenger ribonucleic acid; PCr: polymerase chain reaction;
PI: principal investigator; PIS: participant information sheet; PT: physiotherapy;
QQ: questionnaire; RF: radiofrequency; RNA: ribonucleic acid; RyR: ryanodine
receptor; SAE: serious adverse event; SAP: statistical analysis plan;
SD: standard deviation; SERCA: sarco/endoplasmic reticulum Ca2+-ATPase;
SES: self-efficacy scale; SIP: sickness impact profile; SSL-D: social support list
discrepancy; SSL-I: social support list interactions; SSL-N: social support list
negative Interactions; TIRM: turbo inversion recovery magnitude;
TCTU: Tayside Clinical Trials Unit; TRuST: Tayside randomisation system;
VAS: visual analogue scale; 6MWT: 6-minute walk test.
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